Universal reference book for medicines

Active ingredient: famotidine

Type: The blocker of histamine H 2 -receptors.
Antiulcer drug
Manufacturer: Chemical-Pharmaceutical Plant Akrihin (Russia)
Composition, form of production and packaging
Tablets covered with a film coat of
white or white with a grayish or yellowish hue;
on the bend - white or almost white.
1 tab.

famotidine 20 mg

Excipients: lactose, potato starch, silicon dioxide colloid (aerosil), talc, magnesium stearate.

Sheath composition: hypromellose (hydroxypropylmethylcellulose), macrogol, glycerol, talc, titanium dioxide, lactose.

10 pieces.
- packings cellular planimetric (2) - packs cardboard.

Description of the drug approved by the manufacturer for the printed edition of 2008.


Blocker H 2 -gistaminovyh receptors III generation.
Suppresses basal and hydrochloric acid products stimulated by histamine, gastrin and acetylcholine. Reduces the activity of pepsin. Strengthens the protective mechanisms of the gastric mucosa and promotes the healing of damage associated with the action of hydrochloric acid (including cessation of gastrointestinal bleeding and cicatrization of stress ulcers) by increasing the formation of gastric mucus, the content of glycoproteins in it, stimulating the secretion of bicarbonate by the gastric mucosa, endogenous synthesis of prostaglandins in it and the rate of regeneration.
Essentially does not change the concentration of gastrin in the plasma.
It weakly inhibits the oxidase system of cytochrome P450 in the liver.
After oral administration, the effect begins after 1 hour, reaches a maximum within 3 hours.
The duration of the drug in a single dose depends on the dose and is from 12 to 24 hours.

After oral administration, it is rapidly absorbed from the digestive tract.
After ingestion of Cmax in blood plasma is achieved within 1-3.5 hours. Bioavailability - 40-45%, increases with admission with food and decreases with the use of antacids. The connection with plasma proteins is 15-20%. 30-35% of famotidine is metabolized in the liver (with the formation of S-oxide). Elimination, mainly, occurs through the kidneys: 27-40% of the drug is excreted in the urine unchanged. T 1/2 - 2.5-4 hours, in patients with CC below 30 ml / min increases to 10-12 hours. In patients with severe renal failure (CC below 10 ml / min), it increases to 20 hours. It penetrates the placental barrier and excreted in breast milk.

- peptic ulcer of the duodenum and stomach in the phase of exacerbation, prevention of relapses;

- treatment and prevention of symptomatic gastric and duodenal ulcers (associated with the use of non-steroidal anti-inflammatory drugs, stress,

postoperative ulcers);

- functional dyspepsia associated with increased secretory function of the stomach;

- reflux-esophagitis, erosive esophagitis;

- Zollinger-Ellison syndrome;

- erosive gastroduodenitis;

- prevention of recurrent bleeding from the upper gastrointestinal tract;

- prevention of aspiration of gastric juice in general anesthesia (Mendelssohn syndrome).


With peptic ulcer of the stomach and duodenal ulcer in the phase of exacerbation, symptomatic ulcers , erosive gastroduodenitis usually prescribed 20 mg 2 times / day or 40 mg 1 time / day at night. If necessary, the daily dose can be increased to 80-160 mg. The course of treatment is 4-8 weeks.
With dyspepsia associated with increased secretory function of the stomach , appoint 20 mg 1-2 times / day.

In order to prevent recurrences of peptic ulcer , 20 mg 1 time / day before bedtime is prescribed.

When reflux-esophagitis - 20-40 mg 2 times / day for 6-12 weeks.

With Zollinger-Ellison syndrome, the dose of the drug and the duration of the course of treatment are set individually.
The initial dose is usually 20 mg every 6 hours and can be increased to 160 mg every 6 hours.
In renal failure , if the creatinine clearance is less than 30 ml / min or the serum creatinine content is more than 3 mg / 100 ml, the daily dose of the drug should be reduced to 20 mg.


On the part of the digestive system: dry mouth, nausea, vomiting, abdominal pain, loss of appetite, increased activity of hepatic transaminases, constipation, diarrhea, jaundice, hepatitis, acute pancreatitis.

From the nervous system: headache, dizziness, asthenia, drowsiness, insomnia, fatigue, anxiety, depression, nervousness, psychosis, hyperthermia;
cases of development of hallucinations, confusion of consciousness, indistinctness of visual perception are described.
From the cardiovascular system: lowering of arterial pressure, atrioventricular blockade, bradycardia, arrhythmia, vasculitis.

Allergic reactions: urticaria, pruritus, bronchospasm, angioedema, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylactic shock.

From the hemopoiesis: rarely - leukopenia, neutropenia, thrombocytopenia;
in isolated cases - agranulocytosis, pancytopenia, hypoplasia, bone marrow aplasia.
On the part of the reproductive system: with prolonged intake of large doses - giperprolaktinemiya, ginekomastia, amenorrhea, decreased libido, impotence.

From the sense organs: paresis of accommodation, ringing in the ears.

Other: rarely - fever, arthralgia, myalgia, alopecia, dry skin.


- Pregnancy;

- lactation period;

- liver failure;

- childhood;

- Hypersensitivity to the components of the drug.

With caution: cirrhosis of the liver with portosystemic encephalopathy in history, impaired liver function, renal failure, immunodeficiency.


Contraindicated in pregnancy and lactation.


In renal failure , if the creatinine clearance is less than 30 ml / min or the serum creatinine content is more than 3 mg / 100 ml, the daily dose of the drug should be reduced to 20 mg.


Contraindication: liver failure.


Contraindication: children's age


Before starting treatment, it is necessary to exclude the possibility of having a malignant disease of the esophagus, stomach or duodenum.
Famotidine-Acry ® , like all H 2 -gistaminoblockers, it is undesirable to abruptly abolish ("ricochet" syndrome). With long-term treatment in weakened patients, under stress conditions, bacterial lesions of the stomach are possible with the subsequent spread of infection.
H 2 -gistaminoreceptor blockers can counteract the effects of pentagastrin and histamine on the acid-forming function of the stomach, therefore, it is not recommended to use H 2 -histaminoreceptor blockers within 24 hours preceding the test.

H 2 -gistaminoreceptor blockers can suppress the skin reaction to histamine, thus leading to false negative results (it is recommended to stop the use of H 2 -histaminoreceptor blockers before conducting diagnostic skin tests to detect an allergic skin reaction of immediate type).
During treatment, avoid eating foods, beverages and other medications that can cause irritation of the gastric mucosa.

Symptoms: vomiting, motor anxiety, tremor, lowering blood pressure, tachycardia, collapse.

Treatment: gastric lavage, symptomatic therapy, hemodialysis.


Due to the increase in the pH of the contents of the stomach with simultaneous administration, ketoconazole absorption may decrease.

With simultaneous use with antacids, sucralfate, a decrease in the intensity of absorption of famotidine occurs, therefore, a break between taking these drugs should be at least 1-2 hours.

Inhibits the metabolism in the liver of phenazone, aminophenazone, diazepam, hexobarbital, propranolol, metoprolol, lidocaine, phenytoin, theophylline, indirect anticoagulants, glipizide, buformin, metronidazole, caffeine, slow calcium channel blockers.

Increases the absorption of amoxicillin and clavulanic acid.

Drugs that depress the bone marrow increase the risk of developing neutropenia.


On prescription.


List B. In a dry, the dark place at a temperature of no higher than 25 ° C.
Keep out of the reach of children.
Shelf life 3 years.
Do not use after expiration date
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!